BeOne Medicines (ONC) Change in Accured Expenses (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Change in Accured Expenses of -$16.8 million for Q1 2026, down 516.0% year-over-year from $4.0 million in Q1 2025, and down 105.46% quarter-over-quarter from $308.2 million in Q4 2025.
BeOne Medicines (ONC) Change in Accured Expenses (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Change in Accured Expenses for 12 consecutive years, with -$16.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 516.0% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at $290.9 million (up 2970.25% YoY), while the FY2025 annual figure was $311.8 million, up 2201.11% from the prior year.
- Change in Accured Expenses fell to -$16.8 million in Q1 2026 per ONC's latest filing, from $308.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $308.2 million in Q4 2025 and bottomed at -$78.8 million in Q1 2022.
- Historically, Change in Accured Expenses has averaged $29.8 million across 5 years, with a median of $3.2 million in 2022.
- On a YoY basis, Change in Accured Expenses climbed as much as 5479.83% in 2022 and fell as far as 25919.67% in 2022.
- BeOne Medicines' Change in Accured Expenses stood at $44.0 million in 2022, then surged by 309.23% to $180.1 million in 2023, then sank by 108.17% to -$14.7 million in 2024, then surged by 2195.25% to $308.2 million in 2025, then sank by 105.46% to -$16.8 million in 2026.
- Business Quant data shows ONC's Change in Accured Expenses at -$16.8 million in Q1 2026, $308.2 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212.44 Mn |
| Jun 30, 2026 | 212.44 Mn |
| Mar 31, 2026 | -16.82 Mn |
| Mar 31, 2026 | -16.82 Mn |
| Dec 31, 2025 | 308.21 Mn |
| Dec 31, 2025 | 308.21 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | -3.98 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | -14.71 Mn |
| Dec 31, 2024 | -14.71 Mn |
| Sep 30, 2024 | 28.13 Mn |
| Sep 30, 2024 | 28.13 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -660,000.00 |
| Mar 31, 2024 | -660,000.00 |